Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 9/20 | 0.33 |
| ▸ | ABL1 | P00519 | 2/20 | 0.33 |
| ▸ | ABL2 | P42684 | 1/20 | 0.33 |
| ▸ | MAP3K14 | Q99558 | 4/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25584880 | 0.77 | TDP1 (0.47) | GRM5RIPK1MAP3K14 | |
| SCHEMBL25586388 | 0.77 | NPC1 (0.49) | GRM5RIPK1 | |
| SCHEMBL30387134 | 0.76 | RIPK1 (0.47) | GRM5RIPK1GABRA1GABRG2GABRB3 | |
| SCHEMBL25584836 | 0.76 | RIPK1 (0.47) | GRM5RIPK1GABRA1GABRG2GABRB3 | |
| SCHEMBL25586411 | 0.75 | GRM5 (0.40) | GRM5RIPK1MAP3K14 | |
| SCHEMBL23075920 | 0.74 | RIPK1 (0.48) | GRM5RIPK1MAP3K14 | |
| SCHEMBL25584909 | 0.74 | MAP3K14 (0.38) | GRM5RIPK1MAP3K14PKM | |
| SCHEMBL23076327 | 0.72 | RIPK1 (0.48) | GRM5RIPK1PKMSMN1; SMN2GABRA1 | |
| SCHEMBL23081626 | 0.72 | MAP3K14 (0.46) | RIPK1MAP3K14 | |
| SCHEMBL23085749 | 0.72 | MAP3K14 (0.37) | GRM5MAP3K14GABRA1GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167129-A1 | HETEROCYCLIC AMIDE FOR INHIBITING RIP1 KINASE AND USES THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167129-A1 | HETEROCYCLIC AMIDE FOR INHIBITING RIP1 KINASE AND USES THEREOF | RIPK1, RIPK3, RIPK4 | GRM5 3049/4885RIPK1 1/4885ABL1 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.